Want to see IRD full AI Analyst Report?

Opus Genetics (IRD) Stock Forecast & Price Target

1,370 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IRD Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Opus

Genetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IRD Stock 12 Month Forecast

Average Price Target

$13.75

▲(234.55% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Opus Genetics in the last 3 months. The average price target is $13.75 with a high forecast of $20.00 and a low forecast of $8.00. The average price target represents a 234.55% change from the last price of $4.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","21":"$21","5.25":"$5.25","10.5":"$10.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.25,10.5,15.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.51,5.701538461538462,6.893076923076923,8.084615384615384,9.276153846153846,10.467692307692309,11.65923076923077,12.850769230769231,14.042307692307693,15.233846153846155,16.425384615384615,17.61692307692308,18.80846153846154,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.51,5.22076923076923,5.931538461538461,6.642307692307693,7.353076923076923,8.063846153846153,8.774615384615384,9.485384615384616,10.196153846153846,10.906923076923077,11.617692307692309,12.32846153846154,13.03923076923077,{"y":13.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.51,4.7784615384615385,5.046923076923076,5.315384615384615,5.583846153846154,5.852307692307692,6.1207692307692305,6.389230769230769,6.657692307692308,6.926153846153846,7.194615384615385,7.4630769230769225,7.731538461538461,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.33,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.14,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.83,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$13.75

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lili (Aurélie) Nsongo

Leerink Partners

$14→$15

Buy

264.96%

Upside

Assigned

10/20/26

Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), United Therapeutics (UTHR)

Debanjana Chatterjee

JonesTrading

$17

Buy

313.63%

Upside

Reiterated

10/19/26

Opus Genetics: Advancing BEST1 Program and Targeting Strategy Supports Buy Rating and Unchanged $17 Price Target

Yun Zhong

Wedbush

$13

Buy

216.30%

Upside

Reiterated

10/19/26

Analysts Are Bullish on These Healthcare Stocks: Opus Genetics (IRD), HUTCHMED (HCM)

Biren Amin

Piper Sandler

$11

Buy

167.64%

Upside

Reiterated

10/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Opus Genetics (NASDAQ: IRD), Medtronic (NYSE: MDT) and Elanco Animal Health (NYSE: ELAN)

Francois Brisebois

LifeSci Capital

$10→$20

Buy

386.62%

Upside

Reiterated

09/12/26

LifeSci Capital Remains a Buy on Opus Genetics (IRD)

Steven Seedhouse

Cantor Fitzgerald

$15

Buy

264.96%

Upside

Reiterated

09/10/26

Analysts' Top Healthcare Picks: CG Oncology, Inc. (CGON), Opus Genetics (IRD)

Andreas Argyrides

Chardan Capital

$13→$16

Buy

289.29%

Upside

Assigned

09/09/26

Opus Genetics price target raised to $16 from $13 at ChardanOpus Genetics price target raised to $16 from $13 at Chardan

Thomas Shrader

BTIG

$12

Buy

191.97%

Upside

Reiterated

09/09/26

Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress

Kostas Biliouris

Oppenheimer

$10→$20

Buy

386.62%

Upside

Reiterated

09/09/26

Opus Genetics price target raised to $20 from $10 at OppenheimerOpus Genetics price target raised to $20 from $10 at Oppenheimer

Matthew Caufield

H.C. Wainwright

Buy

94.65%

Upside

Reiterated

09/08/26

Analysts Are Bullish on These Healthcare Stocks: Rigel (RIGL), Opus Genetics (IRD)

James Molloy

Alliance Global Partners

Buy

118.98%

Upside

Reiterated

08/07/26

Alliance Global Partners Remains a Buy on Opus Genetics (IRD)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

08/06/26

Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028

Lisa Walter

RBC Capital

$10→$9

Buy

118.98%

Upside

Reiterated

08/06/26

Opus Genetics (IRD) Gets a Buy from RBC Capital

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

07/06/26

Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Opus Genetics (IRD)

Debjit Chattopadhyay

Guggenheim

$16

Buy

289.29%

Upside

Initiated

06/04/26

Opus Genetics initiated with a Buy at GuggenheimOpus Genetics initiated with a Buy at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lili (Aurélie) Nsongo

Leerink Partners

$14→$15

Buy

264.96%

Upside

Assigned

10/20/26

Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), United Therapeutics (UTHR)

Debanjana Chatterjee

JonesTrading

$17

Buy

313.63%

Upside

Reiterated

10/19/26

Opus Genetics: Advancing BEST1 Program and Targeting Strategy Supports Buy Rating and Unchanged $17 Price Target

Yun Zhong

Wedbush

$13

Buy

216.30%

Upside

Reiterated

10/19/26

Analysts Are Bullish on These Healthcare Stocks: Opus Genetics (IRD), HUTCHMED (HCM)

Biren Amin

Piper Sandler

$11

Buy

167.64%

Upside

Reiterated

10/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Opus Genetics (NASDAQ: IRD), Medtronic (NYSE: MDT) and Elanco Animal Health (NYSE: ELAN)

Francois Brisebois

LifeSci Capital

$10→$20

Buy

386.62%

Upside

Reiterated

09/12/26

LifeSci Capital Remains a Buy on Opus Genetics (IRD)

Steven Seedhouse

Cantor Fitzgerald

$15

Buy

264.96%

Upside

Reiterated

09/10/26

Analysts' Top Healthcare Picks: CG Oncology, Inc. (CGON), Opus Genetics (IRD)

Andreas Argyrides

Chardan Capital

$13→$16

Buy

289.29%

Upside

Assigned

09/09/26

Opus Genetics price target raised to $16 from $13 at ChardanOpus Genetics price target raised to $16 from $13 at Chardan

Thomas Shrader

BTIG

$12

Buy

191.97%

Upside

Reiterated

09/09/26

Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress

Kostas Biliouris

Oppenheimer

$10→$20

Buy

386.62%

Upside

Reiterated

09/09/26

Opus Genetics price target raised to $20 from $10 at OppenheimerOpus Genetics price target raised to $20 from $10 at Oppenheimer

Matthew Caufield

H.C. Wainwright

Buy

94.65%

Upside

Reiterated

09/08/26

Analysts Are Bullish on These Healthcare Stocks: Rigel (RIGL), Opus Genetics (IRD)

James Molloy

Alliance Global Partners

Buy

118.98%

Upside

Reiterated

08/07/26

Alliance Global Partners Remains a Buy on Opus Genetics (IRD)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

08/06/26

Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028

Lisa Walter

RBC Capital

$10→$9

Buy

118.98%

Upside

Reiterated

08/06/26

Opus Genetics (IRD) Gets a Buy from RBC Capital

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

07/06/26

Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Opus Genetics (IRD)

Debjit Chattopadhyay

Guggenheim

$16

Buy

289.29%

Upside

Initiated

06/04/26

Opus Genetics initiated with a Buy at GuggenheimOpus Genetics initiated with a Buy at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

OVIDOvid Therapeutics

OMCLOmnicell

IMUXImmunic

HITIHigh Tide

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Opus Genetics

3 Months

Albert LoweCraig-Hallum

Success Rate

9/11 ratings generated profit

Average Return

+32.69%

Copying Albert Lowe's trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +32.69% per trade.

1 Year

Debanjana ChatterjeeJonesTrading

Success Rate

14/19 ratings generated profit

Average Return

+109.83%

Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +109.83% per trade.

2 Years

Debanjana ChatterjeeJonesTrading

Success Rate

14/19 ratings generated profit

Average Return

+128.51%

Copying Debanjana Chatterjee's trades and holding each position for 2 Years would result in 73.68% of your transactions generating a profit, with an average return of +128.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IRD Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IRD has received 29 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IRD average Analyst price target in the past 3 months is 13.75.

Each month's total comprises the sum of three months' worth of ratings.

IRD Financial Forecast

IRD Earnings Forecast

Next quarter’s earnings estimate for IRD is -$0.15 with a range of -$0.18 to -$0.05. The previous quarter’s EPS was -$0.14. IRD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IRD has Performed in-line its overall industry.

IRD Sales Forecast

Next quarter’s sales forecast for IRD is $1.55M with a range of $0.00 to $3.60M. The previous quarter’s sales results were $755.00K. IRD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IRD has Performed in-line its overall industry.

IRD Stock Forecast FAQ

What is IRD’s average 12-month price target, according to analysts?

Based on analyst ratings, Opus Genetics’s 12-month average price target is 13.75.

What is IRD’s upside potential, based on the analysts’ average price target?

Opus Genetics has 234.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IRD a Buy, Sell or Hold?

Opus Genetics has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Opus Genetics’s price target?

The average price target for Opus Genetics is 13.75. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $8.00. The average price target represents 234.55% Increase from the current price of $4.11.

What do analysts say about Opus Genetics?

Opus Genetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of IRD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Opus Genetics (IRD) Stock Forecast & Price Target

IRD Analyst Ratings

IRD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Opus Genetics

IRD Analyst Recommendation Trends

IRD Financial Forecast

IRD Earnings Forecast

IRD Sales Forecast

IRD Stock Forecast FAQ

Detailed List of Analyst Forecasts